Trade Neurocrine Biosciences, Inc. - NBIX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.34 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.7 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 124.98 |
| Open | 124.31 |
| 1-Year Change | 13.29% |
| Day's Range | 124.31 - 126.24 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 21, 2024 | 124.98 | 2.32 | 1.89% | 122.66 | 125.90 | 121.68 |
| Nov 20, 2024 | 122.88 | 3.84 | 3.23% | 119.04 | 123.67 | 118.80 |
| Nov 19, 2024 | 118.72 | 2.48 | 2.13% | 116.24 | 119.67 | 114.59 |
| Nov 18, 2024 | 117.34 | 0.91 | 0.78% | 116.43 | 118.18 | 115.98 |
| Nov 15, 2024 | 117.38 | -3.37 | -2.79% | 120.75 | 122.29 | 117.00 |
| Nov 14, 2024 | 122.36 | -3.02 | -2.41% | 125.38 | 125.38 | 122.03 |
| Nov 13, 2024 | 125.47 | -1.53 | -1.20% | 127.00 | 127.74 | 125.06 |
| Nov 12, 2024 | 126.96 | 0.61 | 0.48% | 126.35 | 128.09 | 125.24 |
| Nov 11, 2024 | 127.09 | 2.12 | 1.70% | 124.97 | 129.38 | 124.53 |
| Nov 8, 2024 | 125.35 | 1.65 | 1.33% | 123.70 | 126.18 | 123.44 |
| Nov 7, 2024 | 123.90 | -0.55 | -0.44% | 124.45 | 126.42 | 123.23 |
| Nov 6, 2024 | 125.23 | 1.12 | 0.90% | 124.11 | 126.36 | 121.88 |
| Nov 5, 2024 | 121.41 | 2.46 | 2.07% | 118.95 | 121.81 | 118.88 |
| Nov 4, 2024 | 120.43 | -0.86 | -0.71% | 121.29 | 122.24 | 119.37 |
| Nov 1, 2024 | 121.86 | 2.14 | 1.79% | 119.72 | 122.47 | 119.72 |
| Oct 31, 2024 | 120.14 | -1.55 | -1.27% | 121.69 | 122.52 | 119.21 |
| Oct 30, 2024 | 124.27 | 0.07 | 0.06% | 124.20 | 131.01 | 123.78 |
| Oct 29, 2024 | 116.09 | 0.73 | 0.63% | 115.36 | 116.81 | 114.97 |
| Oct 28, 2024 | 115.80 | 1.00 | 0.87% | 114.80 | 117.76 | 114.69 |
| Oct 25, 2024 | 115.92 | 0.97 | 0.84% | 114.95 | 117.30 | 113.41 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Neurocrine Company profile
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Neurocrine Biosciences, Inc. revenues increased 8% to $1.13B. Net income decreased 78% to $89.6M. Revenues reflect Net product sales increase of 10% to $1.09B. Net income was offset by General and administrative -others increase of 36% to $497.5M (expense), Research and development - others increase of 16% to $279.7M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 110M auth. 55,200,641 issd. Insiders own 1.73%. IPO: 5/96, 4,394,286 shares (1,214,286 by the Company) @ $10.50 by Robertson, Stephens & Co. LLC. PO: 12/00, 3M shares @ $30 by Robertson Stephens. PO 12/01, 3.5M shares @ $46.75 by Deutsche Banc Alex. Brown. FY'00 Q's are restated.
| Industry: | Bio Therapeutic Drugs |
12780 El Camino Real
SAN DIEGO
CALIFORNIA 92130-2042
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com